Biologicals in severe chronic rhinosinusitis with nasal polyps: translation to clinical practice while waiting for head-to-head studies

J L Boechat; B Sousa-Pinto; L Delgado; D Silva

doi:10.4193/Rhin22.436

Biologicals in severe chronic rhinosinusitis with nasal polyps: translation to clinical practice while waiting for head-to-head studies

Rhinology. 2023 Jun 1;61(3):283-286. doi: 10.4193/Rhin22.436.

Authors

J L Boechat¹, B Sousa-Pinto², L Delgado³, D Silva⁴

Affiliations

¹ Clinical Immunology Service, Internal Medicine Department, Faculty of Medicine, Universidade Federal Fluminense, Niteroi/RJ, Brazil; Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal; Center for Health Technology and Services Research (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal.
² Center for Health Technology and Services Research (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal; MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
³ Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal; Center for Health Technology and Services Research (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal;Servico de Imunoalergologia, Centro Hospitalar de SÃ£o JoÃ£o, E.P.E., Porto, Portugal.
⁴ Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal; Servico de Imunoalergologia, Centro Hospitalar de Sao Joao, E.P.E., Porto, Portugal; EPIUnit - Institute of Public Health, University of Porto, Laboratory for Integrative and Translational Research in Population Health (ITR), University of Porto, Porto, Portugal.

PMID: 36946510
DOI: 10.4193/Rhin22.436

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1.0-2.6% of the population (1) and results in relevant direct and indirect costs. Recently, several randomized controlled trials (RCTs) with Type 2-targeting biologicals (anti-IL4RÎ±, anti-IL5R, anti-IL5 and anti-IgE) opened a new treatment field for patients refractory to first-line treatments (2,3).

MeSH terms

Biological Products* / therapeutic use
Chronic Disease
Humans
Nasal Polyps* / drug therapy
Rhinitis* / drug therapy
Sinusitis* / drug therapy

Substances

Biological Products